Avita Therapeutics, Inc. (RCEL) is a publicly traded company in the Unknown sector. Across all available filings, 17 corporate insiders have executed 94 transactions totaling $4.4M, demonstrating a bearish sentiment with -$3.6M in net insider flow. The most recent transaction on Aug 28, 2025 involved a purchase of 10,000 shares valued at $45.0K.
No significant insider buying has been recorded for RCEL in the recent period.
No significant insider selling has been recorded for RCEL in the recent period.
Based on recent SEC filings, insider sentiment for RCEL is bearish with an Insider Alignment Score of 9/100 and a net flow of -$3.6M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Avita Therapeutics, Inc. (RCEL) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 17 insiders are actively trading RCEL stock, having executed 94 transactions in the past 90 days. The most active insider is Michael S. Perry (Executive), who has made 20 transactions totaling $4.7M.
Get notified when executives and directors at RCEL file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Aug 28, 2025 | Mcnamara Robert | Executive | Purchase | 10,000 | $4.50 | $45.0K | |
| Aug 26, 2025 | D. O'toole David | Executive | Purchase | 2,000 | $4.52 | $9.0K | |
| Aug 19, 2025 | Mcnamara Robert | Executive | Purchase | 10,000 | $5.00 | $50.0K | |
| Aug 12, 2025 | D. O'toole David | Executive | Purchase | 2,000 | $4.81 | $9.6K | |
| Aug 19, 2024 | Mcnamara Robert | Executive | Award | 10,000 | $9.00 | $90.0K | |
| Jun 5, 2024 | Guy Vance Cary | Executive | Award | 9,200 | $N/A | $0 | |
| Jun 5, 2024 | Mcnamara Robert | Executive | Award | 9,200 | $N/A | $0 | |
| Jun 5, 2024 | Stern Reed Jan | Executive | Award | 9,200 | $N/A | $0 | |
| Jun 5, 2024 | Curnock Cook Jeremy | Executive | Award | 9,200 | $N/A | $0 | |
| Jun 5, 2024 | Crowe Suzanne | Executive | Award | 9,200 | $N/A | $0 | |
| Jun 5, 2024 | Panaccio Lou | Executive | Award | 9,200 | $N/A | $0 | |
| May 31, 2024 | D. O'toole David | Executive | Award | 2,240 | $8.17 | $18.3K | |
| May 31, 2024 | Shiroma Donna | Executive | Award | 2,225 | $8.17 | $18.2K | |
| May 30, 2024 | D. O'toole David | Executive | Purchase | 500 | $8.60 | $4.3K | |
| May 30, 2024 | D. O'toole David | Executive | Purchase | 500 | $9.20 | $4.6K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 13 | $4.0M | 73.1% |
Exercise(M) | 1 | $898.5K | 16.6% |
Purchase(P) | 27 | $406.9K | 7.5% |
Award(A) | 52 | $149.2K | 2.8% |
Other(J) | 1 | $0 | 0.0% |
Insider selling pressure at Avita Therapeutics, Inc. has increased, with 17 insiders executing 94 transactions across all time. Total sales of $4.0M significantly outpace purchases of $406.9K, resulting in a net outflow of $3.6M. This selling activity appears largely discretionary, which may warrant closer attention from investors.